文献速递临床试验与 GCP基础与转化研究

姜黄素-胡椒碱补充对COVID-19重症ICU患者临床状态、死亡率、氧化应激和炎症标志物影响的随机对照试验方案摘要

Effect of curcumin-pipeine supplementation on clinical status, mortality rate, oxidative stress, and inflammatory markers in critically ill ICU patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-07-06

本研究为随机、安慰剂对照、双盲、平行臂临床试验方案,计划纳入60例COVID-19 ICU患者,1:1随机接受姜黄素-胡椒碱胶囊(每日1500 mg姜黄素+15 mg胡椒碱)或安慰剂7天,主要结局为发热、呼吸频率和血氧饱和度正常化时间,次要结局包括死亡率、ICU住院时长及炎症和器官功能标志物。

要点

  • 姜黄素-胡椒碱组每日1500 mg姜黄素+15 mg胡椒碱,分3次口服或肠内喂养后给药,持续7天。
  • 主要结局为发热、呼吸频率和血氧饱和度正常化时间,死亡率随访至28天。
  • 样本量60例(每组30例),按性别分层区组随机,双盲设计。

核心结论

  • 该方案旨在评估姜黄素-胡椒碱联合补充对COVID-19 ICU患者氧化应激、临床症状和死亡率的影响,尚待试验完成后验证。

研究设计与样本

  • 随机、安慰剂对照、双盲、平行臂临床试验,计划纳入60例确诊COVID-19的ICU患者,1:1随机分组。
  • 干预组每日接受3粒胶囊(每粒含500 mg姜黄素+5 mg胡椒碱,总计1500 mg姜黄素+15 mg胡椒碱),对照组接受匹配安慰剂(每粒505 mg麦芽糊精,总计1515 mg/日),疗程7天。
  • 随机化采用分层区组随机(按性别分层,区组大小4),由独立统计师生成序列,使用密封不透明连续编号信封分配。

关键数值与推荐

  • 纳入标准:年龄20-75岁、PCR确诊COVID-19、入住ICU。
  • 排除标准:当前使用肠外营养支持、先天性障碍/免疫疾病/肾功能不全/肝功能不全/胰腺炎病史、对姜黄和胡椒等草药过敏史、规律使用华法林等抗凝药物。
  • 主要结局:从开始补充至发热、呼吸频率和血氧饱和度正常化的时间。
  • 次要结局:死亡率、ICU住院时长、体温、血氧饱和度水平、呼吸机依赖、呼吸频率、CRP、ESR、肝标志物(ALT、AST、LDH)、肾功能标志物(BUN、肌酐)。
  • 所有参数在基线和第7天评估,死亡率在4周(28天)时收集。

临床怎么用

  • 该方案为研究设计,尚未提供临床实践推荐;若试验完成,可能为COVID-19 ICU患者的辅助营养干预提供证据。

局限性

  • 该文为研究方案摘要,未报告试验结果,无法评估干预效果。
  • 样本量较小(60例),随访时间较短(干预7天,死亡率随访28天)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to investigate the efficacy of curcumin-piperine co-supplementation on oxidative stress factors, clinical symptoms, and mortality rate in patients with coronavirus (COVID-19) admitted to the intensive care unit (ICU). TRIAL DESIGN: This study is a randomized, placebo-controlled, double-blind, parallel-arm clinical trial. PARTICIPANTS: The study participants will be recruited from patients admitted to the ICU of Al-Zahra hospital with a definitive diagnosis of COVID-19. The inclusion criteria are aged between 20 and 75 years, confirmation of COVID-19 based on the PCR test, and admitted to the ICU. The exclusion criteria include the present use of parenteral nutrition support, a history of underlying diseases such as congenital disorders, immune diseases, renal and hepatic insufficiency, and pancreatitis, a history of sensitivity to herbal remedies such as turmeric and pepper, and regular use of anticoagulant drugs such as warfarin. This study will be performed in the Al-Zahra hospital, an academic hospital affiliated with Isfahan University of Medical Sciences, Isfahan, Iran. INTERVENTION AND COMPARATOR: Sixty eligible patients will be randomly assigned, in a 1:1 ratio, to receive curcumin-piperine capsules (three capsules/day; each capsules containing 500 mg curcumin plus 5 mg piperine; in total 1500 mg curcumin and 15 mg piperine/daily) for seven days (n=30) or matching placebo capsules (three capsules/day; each capsules containing 505 mg maltodextrin; totally 1515 mg, maltodextrin/ daily) for same duration (n=30). Capsules will be administered after oral or enteral feeding at 9, 15 and 21 o'clock. MAIN OUTCOMES: The primary outcome is the time from initiation of supplementation (curcumin-piperine or placebo) to normalization of fever, respiratory rate, and blood oxygen saturation. The secondary outcomes are the mortality rate, length of stay in ICU, temperature, levels of blood oxygen saturation, ventilator dependency, respiratory rate, levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), levels of liver markers (ALT, AST, LDH), and levels of kidney function markers (BUN, Creatinine). FOLLOW UP: All of the parameters will be assessed at baseline and end of the study (7 days intervention). In addition, the rate of mortality will be collected after 4 weeks (28 days' mortality in the ICU, 4 weeks follow up). RANDOMISATION: Eligible patients will be randomly assigned to either the intervention group (Curcumin-piperine) or the control group (Placebo). Randomization sequences will be generated using an electronic table of random numbers to allocate the included participants into either control or intervention groups (in a 1:1 ratio) using the stratified block randomization method. Stratification was conducted according to sex (male and female), with a block size of four. The allocation sequences will be prepared by an independent statistician and will be kept inside sealed, opaque, and consecutively numbered envelopes. Participants, investigators, nurses, and physicians will be unaware of the trial-group assignment. BLINDING (MASKING): This study is a double-blind clinical trial (participants, investigators, nurses, and physicians). The curcumin-piperine and placebo supplements will be similar in the terms of texture, taste, color, odor, and weight. Both tablets will be provided in containers that are completely identical in weight, shape, labeling, and packaging. All participants, investigators, nurses, and physicians will be unaware of the trial-group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The sample size is estimated at 60 participants, including 30 patients in the intervention group and 30 patients in the placebo group. TRIAL STATUS: The protocol is Version 2, registered on May 13, 2021. Recruitment began May 20, 2021, and is anticipated to be completed by September 20, 2021. TRIAL REGISTRATION: This trial has been registered in Iranian Registry of Clinical Trials (IRCT) with the title of "Evaluation of the effect of curcumin-piperine supplementation in patients with coronavirus admitted to the intensive care unit (ICU): a double-blind clinical trial study". IRCT registration number is IRCT20121216011763N52 . The registration date was May 13, 2021. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (File 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Askari G, Alikiaii B, Soleimani D, et al. Effect of curcumin-pipeine supplementation on clinical status, mortality rate, oxidative stress, and inflammatory markers in critically ill ICU patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34229742. doi:10.1186/s13063-021-05372-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。